Etonogestrel-releasing contraceptive implant use by women with sickle cell disease
ESC Congress Library. Queiroz Vilas Boas A. May 10, 2018; 208135; ESC192
Mrs. Andréa Queiroz Vilas Boas
Mrs. Andréa Queiroz Vilas Boas
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
OBJECTIVE: Women with sickle cell disease have an increased risk of pregnancy-related complications and need safe, effective contraceptive methods to prevent unintended pregnancy. The Etonogestrel (ENG)-releasing contraceptive implant is one of the most effective contraceptive available. However, as far as we know, its effects in women with sickle cell disease have never been described. Thus, the objective of this study was to assess metabolic effect of ENG-releasing contraceptive implant in women with sickle cell anemia during twelve months. DESIGN & METHODS:Clinical study, prospective, exploratory and experimental .A Sixteen women with sickle cell disease aged 18 to 40 years-old, non-obese, with pain crisis and without comorbidity were selected. Blood samples were collected to evaluate complete blood count (reticulocytes, hemoglobin, platelets and leukocytes), hepatic function (Alkaline phosphatase, gamma-glutaryl transferase, amino alanine transferase, aspartate amino transferase, total bilirubin and its fractions), Lipid profile (total cholesterol, HDL, LDL and triglycerides), Lactate dehydrogenase (LDH) before, 6 and 12 months after the implant insertion. The statistical analyses used were Paired t-Student test, Wilcoxon Rank Test and frequency, as appropriated. RESULTS: The laboratory variables analyzed showed no difference between the baseline period, 6 and 12 months after the implant insertion. Baseline 6meses 12 meses IMC 21,2±4 21,5±4,5 21,9±4,9 HB 7,4±1,3 7,5±1,1 7,2±1,1 HT 21,0±3,6 21,0±3,3 20,3±3,5 CA 77,0±10,2 78,1±11,4 78,5±10,3 LDH 1238±638 1204±541 1292±710 Reticu 12,1±5 11,8±5,3 13,8±4,4  CONCLUSION: The ENG-releasing contraceptive implant represents an option for contraception in women with sickle cell disease. The partial results of this research showed neither clinical change in laboratory parameters.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings